Table of Content - Breast Cancer Market Size, Share, Trends Report 2032

Breast Cancer Market Segmentation

Breast Cancer Type Outlook (USD Billion, 2018-2030)

Invasive Ductal Carcinoma

Invasive Lobular Carcinoma

Breast Cancer Treatment Outlook (USD Billion, 2018-2030)

Chemotherapy

Surgery & Radiation Therapy

Targeted Therapy

Biologic Therapy

Hormone Therapy

Breast Cancer End User Outlook (USD Billion, 2018-2030)

Hospital Pharmacies

Private Pharmacies

Breast Cancer Regional Outlook (USD Billion, 2018-2030)

North America Outlook (USD Billion, 2018-2030)
- North America Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- North America Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- North America Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- US Outlook (USD Billion, 2018-2030)
- US Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- US Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy

US Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

CANADA Outlook (USD Billion, 2018-2030)

CANADA Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

CANADA Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

CANADA Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Europe Outlook (USD Billion, 2018-2030)
- Europe Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Europe Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Europe Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- Germany Outlook (USD Billion, 2018-2030)
- Germany Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Germany Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Germany Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- France Outlook (USD Billion, 2018-2030)
- France Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- France Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- France Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- UK Outlook (USD Billion, 2018-2030)
- UK Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- UK Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- UK Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- ITALY Outlook (USD Billion, 2018-2030)
- ITALY Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- ITALY Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- ITALY Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies

SPAIN Outlook (USD Billion, 2018-2030)

Spain Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

Spain Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

Spain Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Rest Of Europe Outlook (USD Billion, 2018-2030)

Rest Of Europe Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

REST OF EUROPE Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

REST OF EUROPE Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Asia-Pacific Outlook (USD Billion, 2018-2030)
- Asia-Pacific Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Asia-Pacific Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Asia-Pacific Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- China Outlook (USD Billion, 2018-2030)
- China Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- China Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- China Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- Japan Outlook (USD Billion, 2018-2030)
- Japan Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Japan Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Japan Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- India Outlook (USD Billion, 2018-2030)
- India Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- India Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- India Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- Australia Outlook (USD Billion, 2018-2030)
- Australia Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Australia Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Australia Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies
- Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
- Rest of Asia-Pacific Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Rest of Asia-Pacific Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Rest of Asia-Pacific Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies

Rest of the World Outlook (USD Billion, 2018-2030)
- Rest of the World Breast Cancer by Type
  - Invasive Ductal Carcinoma
  - Invasive Lobular Carcinoma
- Rest of the World Breast Cancer by Treatment
  - Chemotherapy
  - Surgery & Radiation Therapy
  - Targeted Therapy
  - Biologic Therapy
  - Hormone Therapy
- Rest of the World Breast Cancer by End User
  - Hospital Pharmacies
  - Private Pharmacies

Middle East Outlook (USD Billion, 2018-2030)

Middle East Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

Middle East Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

Middle East Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Africa Outlook (USD Billion, 2018-2030)

Africa Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

Africa Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

Africa Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Latin America Outlook (USD Billion, 2018-2030)

Latin America Breast Cancer by Type
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma

Latin America Breast Cancer by Treatment
- Chemotherapy
- Surgery & Radiation Therapy
- Targeted Therapy
- Biologic Therapy
- Hormone Therapy

Latin America Breast Cancer by End User
- Hospital Pharmacies
- Private Pharmacies

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

TABLE OF CONTENTS
1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. GLOBAL BREAST CANCER MARKET, BY TYPE

5.1 INVASIVE DUCTAL CARCINOMA

5.2 INVASIVE LOBULAR CARCINOMA

5.3 OTHER

6. GLOBAL BREAST CANCER MARKET, BY TREATMENT

6.1 CHEMOTHERAPY

6.1.1 ANTIMETABOLITES

6.1.2 ANTHRACYCLINES

6.1.3 TAXANES

6.1.4 ALKYLATING AGENTS.

6.2 SURGERY & RADIATION THERAPY

6.3 TARGETED THERAPY

6.3.1 TYROSINE KINASE INHIBITORS

6.3.2 MONOCLONAL ANTIBODIES

6.4 BIOLOGIC THERAPY

6.5 HORMONE THERAPY

6.5.1 ESTROGEN-RECEPTOR MODULATORS (SERMS)

6.5.2 AROMATASE INHIBITORS

6.5.3 OTHERS

7. GLOBAL BREAST CANCER MARKET, BY END USER

7.1 HOSPITAL PHARMACIES

7.2 PRIVATE PHARMACIES

7.3 OTHER

8. GLOBAL BREAST CANCER MARKET, BY REGION

8.1 INTRODUCTION

8.2 AMERICA

8.2.1 NORTH AMERICA

8.2.1.1 US

8.2.1.2 CANADA

8.2.2 SOUTH AMERICA

8.3 EUROPE

8.3.1 WESTERN EUROPE

8.3.1.1 GERMANY

8.3.1.2 FRANCE

8.3.1.3 ITALY

8.3.1.3 SPAIN

8.3.1.5 UK

8.3.1.6 REST OF WESTERN EUROPE

8.3.2 EASTERN EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 REPUBLIC OF KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 MIDDLE EAST & AFRICA

8.5.1 UNITED ARAB EMIRATES

8.5.2 SAUDI ARABIA

8.5.3 OMAN

8.5.4 KUWAIT

8.5.5 QATAR

8.5.6 REST OF MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 PFIZER

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 NOVARTIS AG

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 F. HOFFMANN-LA ROCHE

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 ASTRAZENECA

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 GLAXOSMITHKLINE

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 SUN PHARMACEUTICAL INDUSTRIES LTD

10.6.1 OVERVIEW

10.6.2 PRODUCT OVERVIEW

10.6.3 FINANCIALS

10.6.4 KEY DEVELOPMENTS

10.7 TEVA PHARMACEUTICAL INDUSTRIES

10.7.1 OVERVIEW

10.7.2 PRODUCT OVERVIEW

10.7.3 FINANCIALS

10.7.4 KEY DEVELOPMENTS

10.8 OTHERS

11 CONCLUSION

12.1 KEY FINDINGS

12.1.1 FROM CEO’S VIEWPOINT

12.1.2 UNMET NEEDS OF THE MARKET

12.2 KEY COMPANIES TO WATCH

12.3 PREDICTION OF ONCOCARE INDUSTRY

13 APPENDIX

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Certified Global Research Member

Key Questions Answered

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights

Tailored for You